Leadership team

Leadership team

Our leadership team has a deep understanding and exceptional experience in their respective fields of expertise which we leverage to guide our approach and deliver the best possible outcomes for our partners.

Chief Executive Officer (CEO)

Jeremie Trochu

Jeremie joined Ardena as our new Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in both publicly traded and privately held companies. Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO, and during his tenure there, led the successful acquisition and integration of multiple companies.

Jeremie Trochu

Jeremie Trochu

Chief Financial Officer (CFO)

Filip Van Herck, CPA

Filip assumed the role of Chief Financial Officer at Ardena in October 2017. Prior to his appointment, he held various positions at Capsugel (following its spin-out from Pfizer) and Lonza (after its acquisition of Capsugel). He was responsible for overseeing the coordination of IPO readiness efforts and the integration of finance departments following the Lonza-Capsugel acquisition. Earlier in his career, Filip worked at Cisco, where he held several financial positions of increasing responsibility. He obtained a degree in Applied Economics from the University of Leuven in Belgium, and a degree in Business Studies from the Michael Smurfit Business School in Ireland. Filip is a Certified Public Accountant (AICPA).

Filip Van Herck, CPA

Filip Van Herck, CPA

Chief Operating Officer (COO) and Division Head, Drug Substance Services

Gerjan Kemperman, PhD

Gerjan has significant leadership experience with 15+ years in the pharma industry. He worked previously at Organon/MSD in various leadership roles. Gerjan co-founded ChemConnection in 2012. He successfully led and grew the company and finally managed its buyout to Mentha Capital in 2018.

Gerjan Kemperman, PhD

Gerjan Kemperman, PhD

Division Head, Drug Product Services

Ariane De Ganck, PhD

Since 2019, Ariane has overseen Ardena’s drug product activities, spearheading successful integration and transformation at Ardena Pamplona and expanding the company’s capabilities to include sterile services.

Ariane De Ganck, PhD
Read full bio

Ariane De Ganck, PhD

Since 2019, Ariane has overseen Ardena's drug product activities, spearheading successful integration and transformation at Ardena Pamplona and expanding the company's capabilities to include sterile services. With over a decade of senior management experience in CRO/CDMO sectors, Ariane excels in leading multidisciplinary teams and is dedicated to team development, fostering networks, and maintaining a customer-centric approach. Her leadership has also been instrumental in driving business development initiatives. Prior to joining Ardena, Ariane made significant contributions to the growth of Biogazelle, a specialized CRO in RNA and DNA biomarker services. Ariane holds a PhD in biomedical sciences, focusing on proteins and oncology
Division Head, Bioanalytical Services

Gunnar Flik, PhD

Gunnar Flik joined Ardena in 2024 as Division Head of Bioanalytical Services. With over 20 years of experience in drug discovery within biotech and CRO environments, Gunnar brings a wealth of strategic vision and entrepreneurial expertise to his role. He is dedicated to developing comprehensive short- and long-term strategic plans aimed at optimizing efficiency, fostering growth, and enhancing profitability within Ardena’s Bioanalysis division.

Gunnar Flik, PhD
Read full bio

Gunnar Flik, PhD

Gunnar Flik joined Ardena in 2024 as Division Head of Bioanalytical Services. With over 20 years of experience in drug discovery within biotech and CRO environments, Gunnar brings a wealth of strategic vision and entrepreneurial expertise to his role. He is dedicated to developing comprehensive short- and long-term strategic plans aimed at optimizing efficiency, fostering growth, and enhancing profitability within Ardena's Bioanalysis division. Prior to joining Ardena, Gunnar served as owner and Managing Director of operations EU of Brains On-Line which was later acquired by Charles River Laboratories (CRL). He led the successful and seamless integration of Brains On-Line into CRL. Gunnar played a pivotal role in the seamless integration of Brains On-Line into CRL, where he subsequently served as Site Director and contributed to strategic initiatives within the Discovery Business Unit, advising on partnerships and M&A activities. Gunnar holds a PhD in Neuropharmacology.
Chief Commercial Officer (CCO)

Guido Wallraff

Guido is an entrepreneurial-minded senior executive with consistent successes in starting, building, growing and improving revenue and profitability of life science product and service businesses. Guido has more than 25 years of experience.

Guido Wallraff

Guido Wallraff

Your molecule, your journey, our mission.

Get in touch to see how we can craft your path to the clinic with dedicated capabilities.